Holen Sie sich die Stockscreener-App
80.61
2.63%
-2.18
Billiontoone Inc Aktie (BLLN) Neueste Nachrichten
BillionToOne to Report Q1 2026 Earnings on May 6 - National Today
BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026 - GlobeNewswire
Top Billiontoone (BLLN) Competitors 2026 - MarketBeat
BLLN Options Volatility — NASDAQ:BLLN - TradingView — Track All Markets
BLLN Options Chain — NASDAQ:BLLN - TradingView — Track All Markets
J.P. Morgan Maintains BillionToOne(BLLN.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Why BillionToOne Shares Keep Sliding Despite Strong Results - TipRanks
BLLN Technical Analysis | Trend, Signals & Chart Patterns | BILLIONTOONE INC CL A (NASDAQ:BLLN) - ChartMill
Civilization Ventures Management, LLC's BillionToOne Inc(BLLN) Holding History - GuruFocus
BillionToOne Inc (BLLN) Shares Gap Down to $84.655 on Apr 9 - GuruFocus
Why BillionToOne’s Hot Rally Is Suddenly Cracking - TipRanks
MacKenzie Scott Has Now Given Over $1 Billion to 1 Area of Higher Education - inc.com
Highlighting BillionToOne And 2 Other Stocks That Investors May Be Undervaluing - Sahm
Why BillionToOne, Inc. Class A Shares Are Surging - TipRanks
Why BillionToOne Stock Is Suddenly Surging Higher - TipRanks
BillionToOne, Inc. (BLLN) Options Chain - Yahoo! Finance Canada
BillionToOne appoints Allen Chen as oncology VP By Investing.com - Investing.com Canada
BillionToOne Q4 2025 slides: profitability achieved amid 113% revenue surge - Investing.com
BillionToOne Appoints Dr. Allen Chen as Vice President of Medica - GuruFocus
BillionToOne appoints Allen Chen as oncology VP - Investing.com
Billiontoone appoints Dr. Allen Chen as vice president of medical affairs and clinical development, oncology - marketscreener.com
Billiontoone Appoints Dr. Allen Chen As Vice President Of Medical Affairs And Clinical Development, Oncology - TradingView — Track All Markets
BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology - Bitget
Guggenheim Maintains BillionToOne(BLLN.US) With Buy Rating, Cuts Target Price to $100 - Moomoo
InvestingPro spotted BillionToOne’s 46% drop four months in advance By Investing.com - Investing.com Australia
Why BillionToOne, Inc. Class A Shares Are Sinking - TipRanks
BillionToOne And 2 More Growth Companies With Strong Insider Ownership - Yahoo Finance
BillionToOne Inc (BLLN) Shares Up 3.33% on Mar 25 - GuruFocus
BillionToOne, Inc.(NasdaqGS: BLLN) added to S&P Global BMI Index - MarketScreener
Piper Sandler reiterates BillionToOne stock rating on NIPT tech By Investing.com - Investing.com Nigeria
Piper Sandler reiterates BillionToOne stock rating on NIPT tech - Investing.com
Billiontoone (BLLN) Stock Trends and Sentiment 2026 $BLLN - MarketBeat
BillionToOne Inc (BLLN) Stock Price Up 3.48% on Mar 16 - GuruFocus
Billiontoone (BLLN) Stock Forecast and Price Target 2026 $BLLN - MarketBeat
BillionToOne (NASDAQ: BLLN) Shares Climb 8% Amid Strong Momentum in Precision Diagnostics Sector - International Business Times Australia
BTIG lowers BillionToOne stock price target on valuation multiples - Investing.com Nigeria
BillionToOne, Inc.: Fundamental Analysis and Financial Ratings | BLLN | US0901681058 - marketscreener.com
BillionToOne Inc (BLLN) Shares Up 6.14% on Mar 13 - GuruFocus
BillionToOne’s Single-Molecule Next-Generation Sequencing Platform Redefines Molecular Diagnostics for Prenatal and Oncology Care 404148 - Minichart
BillionToOne 10-K: Revenue $305.1M, EPS $0.14 - TradingView
Billiontoone (NASDAQ:BLLN) Hits New 1-Year LowHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Billiontoone, Inc. (NASDAQ:BLLN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
1.41%
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):